Vitamin D levels and menopause-related symptoms.

PubWeight™: 1.41‹?› | Rank: Top 5%

🔗 View Article (PMID 24736200)

Published in Menopause on November 01, 2014

Authors

Erin S LeBlanc1, Manisha Desai, Nancy Perrin, Jean Wactawski-Wende, JoAnn E Manson, Jane A Cauley, Yvonne L Michael, Jean Tang, Catherine Womack, Yiqing Song, Karen C Johnson, Mary J O'Sullivan, Nancy Woods, Marcia L Stefanick

Author Affiliations

1: From the 1Center for Health Research, Kaiser Permanente Northwest, Portland, OR; 2Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA; 3University of Buffalo, Buffalo, NY; 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 5Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; 6Department of Epidemiology and Biostatistics, Drexel University School of Public Health, Philadelphia, PA; 7Department of Medicine, Stanford University School of Medicine, Stanford, CA; 8University of Tennessee Health Science Center, Memphis, TN; 9Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA; 10Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN; 11University of Miami, Miami, FL; 12Biobehavioral Nursing, University of Washington, Seattle, WA; and 13Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA.

Articles cited by this

The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 23.10

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr (2000) 11.69

Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73

Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA (2006) 4.39

Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60

A prospective population-based study of menopausal symptoms. Obstet Gynecol (2000) 3.27

Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry (2004) 3.13

The normal menopause transition. Maturitas (1992) 3.07

The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol (2003) 3.03

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70

Criterion validity and reliability of the SF-36 in a population sample. Qual Life Res (1994) 2.68

Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol (2007) 2.65

The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol (2003) 2.64

Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med (2008) 2.64

National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med (2005) 2.57

Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause (2010) 2.50

The Women's Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol (2003) 2.42

Symptom experience after discontinuing use of estrogen plus progestin. JAMA (2005) 2.32

Reliability and validity of the Women's Health Initiative Insomnia Rating Scale. Psychol Assess (2003) 2.10

Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med (2008) 2.06

The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr (1999) 2.03

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol (2005) 2.01

Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst (1995) 1.94

Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause (2009) 1.86

Calcium absorption in women: relationships to calcium intake, estrogen status, and age. J Bone Miner Res (1989) 1.82

Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol (1998) 1.70

Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr (2010) 1.67

The impact of menopausal symptoms on work ability. Menopause (2012) 1.49

Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health (2001) 1.48

Vitamin D3 enhances mood in healthy subjects during winter. Psychopharmacology (Berl) (1998) 1.47

A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry (2004) 1.47

Evaluation of a simplified vitamin supplement inventory developed for the Women's Health Initiative. Public Health Nutr (1999) 1.45

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat (2009) 1.37

Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J Nutr Health Aging (1999) 1.28

Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas (2002) 1.17

The role of serotonin in hot flushes. Maturitas (2000) 1.15

Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: a randomized controlled trial. Endocr Pract (2009) 1.07

What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol (2009) 1.06

Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci (2006) 0.99

Management of menopause-related symptoms. Evid Rep Technol Assess (Summ) (2005) 0.98

Vasomotor symptoms and well-being in the climacteric years. Maturitas (1996) 0.96

The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int (1986) 0.95

Factors associated with quality of life in a cohort of postmenopausal women. Gynecol Endocrinol (2006) 0.94

Vasomotor symptoms in menopause: where we've been and where we're going. J Womens Health (Larchmt) (2006) 0.91

Understanding the menopausal experiences of professional women. Menopause (2009) 0.90

Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study. Menopause (2009) 0.88

Health profile of middle-aged women: The Women's Health in the Lund Area (WHILA) study. Hum Reprod (2002) 0.82

Women, work, and menopause. Menopause (2012) 0.79

Effects of menopausal hot flashes on mental workload. Ind Health (2011) 0.77

Articles by these authors

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 41.22

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35

The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA (2003) 11.39

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50

Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06

Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05

Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97

Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med (2003) 9.57

A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03

Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89

Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73

Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70

Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64

Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32

Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19

Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77

National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68

A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40

Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA (2013) 7.19

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12

Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA (2006) 7.09

Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med (2009) 6.86

A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85

Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66

Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51

Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med (2014) 6.51

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46

Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16

Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA (2007) 6.02

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA (2008) 5.92

Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86

Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis (2006) 5.82

Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81

Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75

Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med (2004) 5.67

Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48

Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 5.35

Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22

Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14

Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13

A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med (2008) 5.11

Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med (2010) 5.05

High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00

Physical activity, including walking, and cognitive function in older women. JAMA (2004) 4.90

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87

Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83

Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80